LENZ Therapeutics, Inc. (LENZ)
NASDAQ: LENZ · Real-Time Price · USD
3.860
-0.100 (-2.53%)
At close: Sep 29, 2026, 4:00 PM EDT
3.900
+0.040 (1.04%)
After-hours: Sep 29, 2026, 7:30 PM EDT
LENZ Therapeutics Stock Forecast
LENZ's stock price has decreased by -90.82% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
According to 7 analysts polled by S&P Global, LENZ Therapeutics stock has a consensus rating of "Buy" and an average price target of $24. The average 1-year stock price forecast is 521.76% higher than the current stock price, while the lowest is $7.00 (+81.35%) and the highest is $60 (+1,454.40%).
Price Target: $24 (+521.76%)
Analyst Consensus: Buy
Price Target
Chart* Price targets were last updated on Aug 13, 2026.
Analyst Ratings
The average analyst rating for LENZ Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 | Aug '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 6 | 6 | 6 | 5 |
| Buy | 1 | 1 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 1 | 1 | 1 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 7 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Bank of America Securities | Bank of America Securities | Hold Downgrades $7 | Hold | Downgrades | $7 | +81.35% | Aug 13, 2026 |
| William Blair | William Blair | Buy Maintains n/a | Buy | Maintains | n/a | n/a | Aug 12, 2026 |
| Piper Sandler | Piper Sandler | Hold Maintains $12 → $7 | Hold | Maintains | $12 → $7 | +81.35% | Aug 12, 2026 |
| Citi | Citi | Buy Maintains $20 → $10 | Buy | Maintains | $20 → $10 | +159.07% | Aug 12, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $38 | Buy | Reiterates | $38 | +884.46% | Aug 12, 2026 |
Financial Forecast
Revenue This Year
16.99M
from 19.09M
Decreased by -10.99%
Revenue Next Year
42.99M
from 16.99M
Increased by 153.04%
EPS This Year
-4.18
from -2.85
EPS Next Year
-3.08
from -4.18
EPS and Forward PE are based on non-GAAP adjusted numbers.